Company intelligence / Profile preview
Curocell Inc.
Daejeon, Daejeon, South Koreacurocell.co.kr ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Curocell Inc. develops innovative CAR-T cell therapies using its proprietary OVIS™ technology to overcome limitations of existing treatments. Its lead asset, anbal-cel, targets multiple myeloma and T-cell lymphoma and may be the first homegrown Korean CAR-T therapy. The company has raised over $82 million in funding through Series D and continues to expand its pipeline targeting both blood cancers and solid tumors. It focuses on novel antigen discovery, improved efficacy/safety of cell therapies, and automation of quality analysis.
- Therapeutic areas
- HematologyOncology
- Modalities
- CAR-T cell therapies (chimeric antigen receptor T-cell therapies)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Curocell Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curocell Inc..